# Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

> **NCT01160094** · — · COMPLETED · sponsor: **Novartis** · enrollment: 288 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Treatment

## Key facts

- **NCT ID:** NCT01160094
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2016-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160094, "Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01160094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*